[spb_row element_name=”Row” wrap_type=”content-width” row_bg_type=”color” color_row_height=”content-height” bg_type=”cover” parallax_image_height=”content-height” parallax_image_movement=”fixed” parallax_image_speed=”0.5″ bg_video_loop=”yes” parallax_video_height=”window-height” parallax_video_overlay=”none” row_overlay_opacity=”0″ row_padding_vertical=”0″ row_margin_vertical=”30″ remove_element_spacing=”no” vertical_center=”false” inner_column_height=”col-natural” row_expanding=”no” row_animation=”none” row_animation_delay=”0″ minimize_row=”no” simplified_controls=”no” custom_css_percentage=”no” custom_css=”margin-top: 15px;margin-bottom: 15px;border-top: 0px ;border-left: 0px ;border-right: 0px ;border-bottom: 0px ;padding-top: 30px;padding-left: 0px;padding-right: 0px;padding-bottom: 0px;” border_styling_global=”default” width=”1/1″ el_position=”first last”] [spb_text_block title=”Development pipeline” animation=”none” animation_delay=”0″ simplified_controls=”yes” custom_css_percentage=”no” padding_vertical=”0″ padding_horizontal=”0″ margin_vertical=”0″ custom_css=”margin-top: 0px;margin-bottom: 0px;border-top: 0px ;border-left: 0px ;border-right: 0px ;border-bottom: 0px ;padding-top: 0px;padding-left: 0px;padding-right: 0px;padding-bottom: 0px;” border_size=”0″ border_styling_global=”default” width=”1/1″ el_position=”first last”]
| NCT ID | Research | Preclin | Phase 1 | Phase 2 | Phase 3 |
|---|
| Colorectal Cancer | ||
| 03750786 | AGENT ISO-CC-007, Phase III. Pivotal study with 440 patients undergoing first line treatment for metastatic colorectal cancer (mCRC). Clinical Trial >> | |
| 01681472 | ISO-CC-002, a Phase I/II Pharmacockinetics and pharmacodynamics clinical investigation of arfolitixorin (Modufolin®) in Plasma, Tumor and Adjacent Mucosa in Patients with Colon Cancer. Clinical Trial >> | |
| 01397305 | ISO-MC-091, Phase I/II Study where Pemetrexed is co-administered with arfolitixorin (Modufolin®) to newly diagnosed, non-cytostatically-treated patients with resectable Rectal Cancer. Clinical Trial >> | |
| 02244632 | ISO-CC-005, Phase I/II arfolitixorin (Modufolin®) in Combination with 5-Fluorouracil Alone or with Irinotecamn or Oxaliplatin ± bevacizumab in patients with colorectal cancer. Clinical Trial >> | |
| Osteosarcoma | ||
| 02383901 | ISO-MTX-OB1, A Retrospective Non-intervention Study tto investigate how rescue treatment with folates in patients with osteosarcoma works in clinical context. Clinical Trial >> | |
| 01987102 | ISO-MTX-003, Phase I/II study intended to identify the arfolitixorin (Modufolin®) dose to be used in continued clinical development for in the osteosarcoma indication. Clinical Trial >> |
[/spb_text_block] [/spb_row] [spb_divider type=”standard” text=”Go to top” top_margin=”10px” bottom_margin=”10px” fullwidth=”no” width=”1/1″ el_position=”first last”] [spb_row element_name=”Row” wrap_type=”content-width” row_bg_type=”color” color_row_height=”content-height” bg_type=”cover” parallax_image_height=”content-height” parallax_image_movement=”fixed” parallax_image_speed=”0.5″ bg_video_loop=”yes” parallax_video_height=”window-height” parallax_video_overlay=”none” row_overlay_opacity=”0″ row_padding_vertical=”0″ row_margin_vertical=”30″ remove_element_spacing=”no” vertical_center=”false” inner_column_height=”col-natural” row_expanding=”no” row_animation=”none” row_animation_delay=”0″ minimize_row=”no” simplified_controls=”no” custom_css_percentage=”no” custom_css=”margin-top: 15px;margin-bottom: 15px;border-top: 0px ;border-left: 0px ;border-right: 0px ;border-bottom: 0px ;padding-top: 30px;padding-left: 0px;padding-right: 0px;padding-bottom: 40px;” border_styling_global=”default” width=”1/1″ el_position=”first last”] [spb_text_block title=”Clinical Studies” animation=”none” animation_delay=”0″ simplified_controls=”yes” custom_css_percentage=”no” padding_vertical=”0″ padding_horizontal=”0″ margin_vertical=”0″ custom_css=”margin-top: 0px;margin-bottom: 0px;border-top: 0px ;border-left: 0px ;border-right: 0px ;border-bottom: 0px ;padding-top: 0px;padding-left: 0px;padding-right: 0px;padding-bottom: 0px;” border_size=”0″ border_styling_global=”default” width=”1/1″ el_position=”first last”]
ISOFOL ISÂ CURRENTLY IN PHASE I/II CLINICAL STUDIES
FOR BOTH HDMTX RESCUE AND COLORECTAL CANCER
[/spb_text_block] [spb_text_block animation=”none” animation_delay=”0″ simplified_controls=”yes” custom_css_percentage=”no” padding_vertical=”0″ padding_horizontal=”0″ margin_vertical=”0″ custom_css=”margin-top: 0px;margin-bottom: 0px;border-top: 0px ;border-left: 0px ;border-right: 0px ;border-bottom: 0px ;padding-top: 0px;padding-left: 0px;padding-right: 0px;padding-bottom: 0px;” border_size=”0″ border_styling_global=”default” width=”1/2″ el_position=”first”]
ISO-CC-002
ISO-CC-002 (NCT01681472) is a Phase I/II single-center, blinded, randomized, pharmacokinetic and pharmacodynamic investigation with two doses of arfolitixorin (Modufolin®) compared to levoleucovorin in tumor tissue, adjacent mucosa and plasma for patients with colon cancer admitted for resection of the colon. The study is completed.
[/spb_text_block] [spb_text_block animation=”none” animation_delay=”0″ simplified_controls=”yes” custom_css_percentage=”no” padding_vertical=”0″ padding_horizontal=”0″ margin_vertical=”0″ custom_css=”margin-top: 0px;margin-bottom: 0px;border-top: 0px ;border-left: 0px ;border-right: 0px ;border-bottom: 0px ;padding-top: 0px;padding-left: 0px;padding-right: 0px;padding-bottom: 0px;” border_size=”0″ border_styling_global=”default” width=”1/2″ el_position=”last”]
ISO-MC-091
ISO-MC-091 (NCT01397305) is a Phase I/II single-center, open-label, feasibility extended study of pemetrexed single agent with arfolitixorin (Modufolin®) given to chemo-naïve patients with newly diagnosed operable rectal cancer. The study is currently ongoing but approaching completion and the last patient is undergoing treatment.
[/spb_text_block] [spb_text_block animation=”none” animation_delay=”0″ simplified_controls=”yes” custom_css_percentage=”no” padding_vertical=”0″ padding_horizontal=”0″ margin_vertical=”0″ custom_css=”margin-top: 0px;margin-bottom: 0px;border-top: 0px ;border-left: 0px ;border-right: 0px ;border-bottom: 0px ;padding-top: 0px;padding-left: 0px;padding-right: 0px;padding-bottom: 0px;” border_size=”0″ border_styling_global=”default” width=”1/2″ el_position=”first”]
ISO-CC-005
ISO-CC-005 (NCT02244632) is a Phase I/II, single center, open label study aiming to identify the safety and tolearability of a dose range of arfolitixorin (Modufolin®) in combination with the routine doses of 5-FU and oxaliplatin in patients with colon cancer, stage IV. The study is being initiated at Östra Hospital, Gothenburg, Sweden. The results will be used to define the dose to be documented as efficacious in a blinded multicentre trial in patients with colon cancer, stage IV.
[/spb_text_block] [spb_text_block animation=”none” animation_delay=”0″ simplified_controls=”yes” custom_css_percentage=”no” padding_vertical=”0″ padding_horizontal=”0″ margin_vertical=”0″ custom_css=”margin-top: 0px;margin-bottom: 0px;border-top: 0px ;border-left: 0px ;border-right: 0px ;border-bottom: 0px ;padding-top: 0px;padding-left: 0px;padding-right: 0px;padding-bottom: 0px;” border_size=”0″ border_styling_global=”default” width=”1/2″ el_position=”last”]
ISO-MTX-003
ISO-MTX-003 (NCT01987102) is a Phase I/II open-label, multicenter
clinical trial designed to identify the arfolitixorin (Modufolin®) dose with most favorable safety prospect and confirmed ability to mitigate HDMTX induced toxicity during treatment of osteosarcoma patients. This is the first study in which HDMTX rescue with arfolitixorin (Modufolin®) is investigated. The study is completed.
[/spb_text_block] [/spb_row]
Last updated 02-07-2019
